What Is the Life Expectancy of Stage 4 Cancer?

Stage 4 cancer has no single life expectancy. Median survival ranges from under a year for some aggressive cancers to several years or even decades for others, depending on where the cancer started, where it has spread, how the body is functioning overall, and which treatments are available. A person with stage 4 melanoma today faces a fundamentally different outlook than someone diagnosed ten years ago, while metastatic pancreatic cancer remains stubbornly lethal regardless of era. The numbers people find online are population-level medians, and they obscure an enormous spread of individual outcomes that makes any single figure misleading.

Why There Is No Single Number

Stage 4 means the cancer has spread beyond its original organ to distant parts of the body. But the word “spread” covers vastly different biological situations. A few small bone lesions from prostate cancer behave nothing like widespread liver and lung involvement from colon cancer. The site of the original tumor, the location and number of metastases, the molecular profile of the cancer cells, and the patient’s overall physical condition all push survival in different directions, sometimes by years.

A predictive model built from patients receiving palliative radiation identified six factors that independently shortened life expectancy: lung cancer (versus breast or prostate), age over 60, liver metastases, poor physical functioning, recent hospitalization, and having already been through multiple rounds of chemotherapy.¹ That list gives a sense of how many variables are in play. Two people with “stage 4 cancer” can have almost nothing in common medically.

Survival by Cancer Type

The gap between cancer types at stage 4 is dramatic. Here are some of the better-studied cancers, with the caveat that these are medians: half of patients live longer, and some live much longer.

Lung Cancer

Stage 4 non-small cell lung cancer (NSCLC) has historically been one of the more lethal diagnoses. In a large cohort study, the median survival for stage 4 NSCLC patients who survived at least three months was about 23 months, with five-year survival around 16% and ten-year survival around 5%.² Those numbers have improved substantially in patients whose tumors carry specific genetic mutations that can be targeted with precision drugs. Patients with certain mutations in genes like EGFR or ALK can now have cumulative estimated survival that approaches or exceeds a normal lifespan when targeted therapy works well.³ That is a remarkable shift from an era when metastatic lung cancer was almost uniformly fatal within a year or two.

Breast Cancer

Stage 4 breast cancer survival depends heavily on the cancer’s molecular subtype. Younger patients (under 40) with metastatic breast cancer had a median survival of about 45 months, compared to 33 months for older patients, but this advantage largely disappeared in triple-negative disease.⁴ Hormone receptor-positive, HER2-positive breast cancers tend to respond to more treatment options and carry longer survival, while triple-negative metastatic breast cancer remains the hardest to treat and is associated with the worst outcomes.⁵ The blood-based markers that oncologists increasingly use to track the disease, including circulating tumor cells and circulating tumor DNA, are helping refine which patients within the same subtype are likely to do better or worse.⁶

Melanoma

Melanoma is the cancer where immunotherapy has rewritten the survival story most visibly. Before modern immune checkpoint drugs, the median survival for stage 4 melanoma was under a year, and roughly one in ten patients reached five years.⁷ In a more recent evaluation of 640 patients entering stage 4 between 2014 and 2017, about a third were still alive at least five years later. Among that group, the median survival from stage 4 diagnosis was six years, and the vast majority had stopped treatment entirely and were in complete remission.⁸ Complete remission rates under first-line immunotherapy now exceed 20%, and patients who achieve a complete response have durable disease control, with more than 70% remaining progression-free three years later.⁹ Long-term follow-up data now shows that durable responses can persist even after treatment is stopped, with more than six years of median follow-up confirming this pattern.¹⁰

Prostate Cancer

Metastatic prostate cancer survival varies enormously depending on where it has spread. In a large analysis, patients whose cancer had only reached lymph nodes had a median survival over three and a half years. Bone-only metastases dropped that to about two years, visceral metastases to roughly 16 months, and the combination of bone and visceral involvement brought the median down to about 14 months.¹¹ Visceral spread, meaning involvement of organs like the liver or lungs, is a consistently bad sign across many cancer types, and prostate cancer is no exception.

Colorectal Cancer

When colorectal cancer spreads to the liver, median survival without treatment runs roughly 5 to 20 months.¹² With treatment, survival improves, but performance status remains the dominant predictor. Patients who were still physically active at diagnosis had roughly two and a half times the survival of those who were bedridden or needed frequent assistance.¹³

The Factors That Matter Most

Across nearly all stage 4 cancers, a handful of factors consistently predict who will live longer and who will not. Physical functioning, measured by oncologists using performance status scales, is the single strongest predictor in most analyses. A patient who can still work or handle daily activities independently has a fundamentally different prognosis than one who spends most of the day in bed. In one study of stage 4 patients referred for radiation, the strongest predictors of longer survival were good performance status, fewer than six active tumors, a favorable primary tumor site (breast, kidney, or prostate versus others), and normal blood albumin levels.¹⁴

Where the cancer spreads also matters independently of where it started. Liver metastases are a particularly ominous sign across cancer types. And having metastases outside the skeleton in addition to bone involvement sharply reduces survival: in one prospective study of patients with bone metastases, only about one in five of those with additional spread beyond the bones survived more than six months.¹⁵

When Stage 4 Does Not Mean What It Used to

One of the most important developments in oncology over the past decade is the recognition that not all stage 4 disease is the same. A patient with three small metastases may be in a very different biological situation than one with dozens of tumors throughout the body. The term “oligometastatic disease” describes the state of having only a limited number of metastatic sites, and treating these aggressively can sometimes produce long-term disease control.

A phase 2 randomized trial (SABR-COMET) tested whether ablating all metastatic sites with focused radiation in oligometastatic patients improved outcomes. The five-year survival rate jumped from about 18% with standard palliative treatment to roughly 42% with the aggressive approach.¹⁶ In prostate cancer specifically, an intensified multimodal approach combining surgery, radiation, hormone therapy, and targeted treatment of metastatic sites in oligometastatic patients produced striking results: no prostate cancer deaths during follow-up periods extending to nearly 12 years.¹⁷ These are small studies and highly selected patients, but they illustrate why blanket stage 4 survival statistics can be misleading for people at the favorable end of the spectrum.

How Immunotherapy and Targeted Therapy Changed the Landscape

The survival curves for several stage 4 cancers now have a distinctive shape: a steep initial drop as some patients do not respond, followed by a long tail of patients who achieve durable responses and live for years. This tail is particularly pronounced with immunotherapy. In advanced NSCLC trials, the mean survival gain from immunotherapy was substantially larger than the median gain would suggest, because the patients who responded tended to respond for a long time.¹⁸ That pattern is real but can create misleading expectations. The median tells you where the middle patient lands, which may be quite short. The mean gets pulled upward by the long-surviving minority. Neither number tells an individual patient what will happen to them.

In kidney cancer, targeted therapies have similarly shifted the conversation. Advanced renal cell carcinoma was once considered rapidly fatal and essentially untreatable once it metastasized. Sequential use of targeted agents has turned it into something closer to a chronic disease for a subset of patients, with meaningful improvements in both progression-free and overall survival.¹⁹ The concept of “living with cancer” rather than dying from it is now realistic for certain stage 4 diagnoses, though far from universal.

Clinical Trial Numbers Versus Real Life

Nearly all the survival figures you encounter online originate from clinical trials, and there is a well-documented gap between what trials report and what happens in everyday practice. A meta-analysis covering 29 cancer drug indications found that 97% showed worse survival in the real world than in the trial that led to the drug’s approval. The median difference was about five months shorter in real-world patients, and the overall risk of death was roughly 58% higher.²⁰

A focused study on pembrolizumab (a widely used immunotherapy drug) in stage 4 NSCLC found that real-world median survival was roughly 55% shorter than what the registration trial showed.²¹ This happens because trials enroll healthier, younger, more carefully selected patients. People with poor physical function, serious additional health conditions, or limited access to specialized care are often excluded from trials but make up a significant share of real-world patients. If you are reading survival statistics from a clinical trial, the numbers you see likely overestimate what the average patient in a community oncology practice will experience.

Palliative Care and the Survival Paradox

One counterintuitive finding that has held up across multiple studies: starting palliative care early, alongside active cancer treatment, tends to extend life. In a landmark trial of patients with metastatic NSCLC, those randomly assigned to early palliative care lived a median of 11.6 months compared to 8.9 months for those receiving standard oncology care alone. The early palliative care group also had better quality of life, lower rates of depression, and received less aggressive treatment at the end of life.²² A systematic review and meta-analysis confirmed that early palliative care improved quality of life and was associated with increased likelihood of survival in patients with advanced cancer.²³

The likely mechanism is not that palliative care is a hidden cure. Rather, patients who receive good symptom management and psychological support tend to maintain better physical condition, tolerate treatment better, and make more informed decisions about when aggressive treatment is no longer helping. They also tend to avoid the cycle of emergency hospitalizations and desperate last-minute interventions that can actually hasten death.

How Accurate Are Doctors at Predicting Survival?

If you ask your oncologist how long you have, the answer will be imprecise. Research consistently shows that clinicians, from trainees to senior consultants, tend to overestimate how long patients with advanced cancer will live.²⁴ A more recent study found that oncologists’ median estimates were actually well calibrated on average: about half of patients lived longer than predicted and half lived shorter. But the individual-level accuracy was poor, with only about 28% of estimates qualifying as “precise.”²⁵ In plain terms, your oncologist can give you a reasonable range, but predicting whether any one person will fall at the short end or the long end of that range is something no one can do reliably.

This is worth understanding because patients and families often treat a doctor’s estimate as more precise than it is. A prognosis of “about a year” does not mean death at 12 months. It means the middle of a distribution that includes people who die in three months and people who are still alive in three years. The honest answer, which most experienced oncologists will tell you, is that survival predictions are useful for making broad plans but poor at telling any individual what their future holds.

Where You Get Treated Makes a Difference

The hospital and the treatment team matter more than many patients realize. For metastatic NSCLC, patients treated at the highest-volume facilities had median survival about two months longer than those at the lowest-volume centers, and the mortality difference persisted even after adjusting for patient characteristics.²⁶ A similar pattern holds in advanced ovarian cancer, where being treated by a high-volume provider at a high-volume hospital was associated with significantly better survival compared to low-volume settings.²⁷ Advanced laryngeal cancer showed the same trend, with the lowest death rates at high-volume teaching and research centers.²⁸

This does not mean everyone should travel across the country for treatment. But it does mean that, where feasible, getting at least an initial consultation at a major cancer center to confirm the treatment plan is a reasonable move, especially for less common cancers or cases where the treatment involves newer options like immunotherapy or oligometastatic-directed therapy.

Racial and Socioeconomic Disparities in Stage 4 Survival

Not everyone with the same stage 4 diagnosis gets the same shot at survival. Across five major cancer types, Black patients and those with lower income or public insurance had consistently lower survival rates.²⁹ Even after accounting for differences in access to surgery, radiation, and chemotherapy, the survival gap shrank but did not disappear, suggesting that treatment access alone does not explain the entire disparity.

Insurance status is a particularly strong predictor. Patients with Medicaid or no insurance had roughly 44 to 47% higher risk of dying from their cancer compared to those with private insurance, even after adjusting for age, race, stage, and treatment received.³⁰ In metastatic colorectal cancer specifically, Black patients with private insurance or Medicare were less likely to receive chemotherapy compared to White patients with the same insurance, a gap that disappeared only among Medicaid and uninsured patients.³¹ These patterns point to structural barriers in the healthcare system that go beyond individual biology, and they mean that population-level survival statistics may understate or overstate your personal outlook depending on the resources and care systems available to you.

Why Median Survival Can Be Misleading

The median is the number you will see most often in survival statistics, and it has a specific meaning: the point at which half the patients have died and half are still alive. It is the standard measure in clinical trials because it is relatively stable and easy to compute. But it can be a poor summary of what actually happens to patients, especially in the immunotherapy era.

When a treatment produces durable responses in a minority of patients who then survive for many years, the median barely moves, but the mean (average) survival increases substantially. An analysis of FDA-approved cancer drugs found that the average improvement in median survival across approvals was about 4.6 months, while the average improvement in mean survival was about 6.1 months.³² That gap matters. If you are the patient who responds well to immunotherapy, the median is nearly irrelevant to your experience. If you are the patient who does not respond, the median may actually overestimate your survival. The median describes the group. It does not describe you.

This is not an argument against looking at survival statistics. Understanding the range of outcomes helps with planning, conversations with family, and treatment decisions. But it is an argument against fixating on a single number. Ask your oncologist not just for the median, but for the range of outcomes they have seen in patients with your specific situation, and what proportion of patients achieve long-term responses with the proposed treatment plan. That conversation will be more useful than any number you find in a search engine.